Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade.

MLA

Anastasiou, Panayiotis, et al. “Combining RAS(ON) G12C-Selective Inhibitor with SHP2 Inhibition Sensitises Lung Tumours to Immune Checkpoint Blockade.” Nature Communications, vol. 15, no. 1, Sept. 2024, p. 8146. EBSCOhost, https://doi.org/10.1038/s41467-024-52324-3.

APA

Anastasiou, P., Moore, C., Rana, S., Tomaschko, M., Pillsbury, C. E., de Castro, A., Boumelha, J., Mugarza, E., de Carné Trécesson, S., Mikolajczak, A., Blaj, C., Goldstone, R., Smith, J. A. M., Quintana, E., Molina-Arcas, M., & Downward, J. (2024). Combining RAS(ON) G12C-selective inhibitor with SHP2 inhibition sensitises lung tumours to immune checkpoint blockade. Nature Communications, 15(1), 8146. https://doi.org/10.1038/s41467-024-52324-3

Chicago

Anastasiou, Panayiotis, Christopher Moore, Sareena Rana, Mona Tomaschko, Claire E Pillsbury, Andrea de Castro, Jesse Boumelha, et al. 2024. “Combining RAS(ON) G12C-Selective Inhibitor with SHP2 Inhibition Sensitises Lung Tumours to Immune Checkpoint Blockade.” Nature Communications 15 (1): 8146. doi:10.1038/s41467-024-52324-3.